Vivos CEO to Present at Moody Conference
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The announcement is a routine investor relations activity and is unlikely to have a significant impact on Vivos Therapeutics' stock price or the broader market. It may provide a platform for the company to communicate its recent business trends to institutional investors, potentially supporting investor confidence.
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, announced that its Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody s Ratings Disruptive Growth & Life Sciences Conference. The conference will take place on September 9 and 10, 2026, at The Westin New York Grand Central in New York City. Mr. Huntsman is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. Eastern Time, followed by a question-and-answer session. Company management will also be available for one-on-one meetings with institutional investors throughout the conference. In a statement, Mr. Huntsman highlighted the positive trends in the company's business and expressed enthusiasm about communicating the company's story to the financial markets. This event is primarily a corporate presentation and investor relations activity, with no material operational or financial changes announced.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard